Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.4962 | 0.4962 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4962 | 0.4962 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4962 | 0.4962 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.4962 | 0.4962 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4962 | 0.4962 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.4962 | 0.4962 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0034 | 0 | 0.5 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.4962 | 0.4962 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.4962 | 0.4962 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.4962 | 0.4962 |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | 0.0034 | 0 | 0.5 | |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0034 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.2589 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.7783 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.